Cessation Therapeutics, Inc.
Paul Bremer is an experienced researcher in the field of medicinal chemistry and immunotherapeutics, currently serving as the R&D Director at Cessation Therapeutics, Inc. since 2018. Bremer has held various positions at The Scripps Research Institute since 2011, including Professional Scientific Collaborator, Postdoctoral Researcher, and Graduate Student. Prior experience includes a role as Temporary Research Scientist in Medicinal Chemistry at Vertex Pharmaceuticals, along with several undergraduate research positions at institutions such as Colgate University, the National Institute of Allergy and Infectious Diseases, and the University of Minnesota. Bremer earned a Ph.D. in Medicinal Chemistry / Immunotherapeutics from Scripps Research and a Bachelor of Arts in Chemistry from Colgate University.
This person is not in any teams
Cessation Therapeutics, Inc.
Cessation Therapeutics provides therapeutics for an addiction-free through immunotherapy-based biotech innovation.Cessation Therapeutics is developing novel immunotherapy vaccine candidates and small molecules with the objective of helping millions of families overcome the opioid, heroin, morphine, fentanyl, alcohol and nicotine addiction usedisorders. Cessation Therapeutics is currently developing heroin, opioid and fentanyl addiction vaccines based on the technology licensed from The Scripps Research Institute in La Jolla, California (TSRI) and has commenced planning pre-clinical studies to advance these vaccine candidates into clinical stage.